Scott Alban of AstraZeneca outlines the company’s recent transformation aimed at breaking down barriers and the uncharted territories that it is eager to explore.
Charged with protecting the innovation arising from MedImmune, the global biologics research and development arm of AstraZeneca, as well as AstraZeneca’s innovative medicines and early development biotech units, Scott Alban’s job is far from insignificant.
Alban was behind AstraZeneca and MedImmune’s recent transformation of its global IP organisation to circumvent geographic and cultural barriers between the IP professionals who support pharmaceuticals and biologics across seven global sites.
“We wanted to empower our attorneys and other patent professionals to work collaboratively across multiple therapy areas, technology platforms and therapeutic modalities,” he says.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at firstname.lastname@example.org.
If you have any technical issues please email tech support.
Scott Alban, LSIPR 50 2018, AstraZeneca, MedImmune, biology, research and development, innovation, biotech